Clinical & Translational Science: Individualizing Cancer Immunotherapy
description
Transcript of Clinical & Translational Science: Individualizing Cancer Immunotherapy
![Page 1: Clinical & Translational Science: Individualizing Cancer Immunotherapy](https://reader035.fdocuments.net/reader035/viewer/2022070422/568165d8550346895dd8e8ea/html5/thumbnails/1.jpg)
Clinical & Translational Science:Individualizing Cancer ImmunotherapyScott A. Waldman, MD, PhD, FCPThomas Jefferson University
![Page 2: Clinical & Translational Science: Individualizing Cancer Immunotherapy](https://reader035.fdocuments.net/reader035/viewer/2022070422/568165d8550346895dd8e8ea/html5/thumbnails/2.jpg)
Clinical & Translational Science:
Individualizing Cancer Immunotherapy
Scott A. Waldman, MD, PhD, FCP
Director, Delaware Valley Institute for Clinical and Translational ScienceChair, Department of Pharmacology and Experimental Therapeutics
Director, GI Malignancies Program, Kimmel Cancer CenterThomas Jefferson UniversityPhiladelphia, Pennsylvania
![Page 3: Clinical & Translational Science: Individualizing Cancer Immunotherapy](https://reader035.fdocuments.net/reader035/viewer/2022070422/568165d8550346895dd8e8ea/html5/thumbnails/3.jpg)
Disclosures• I am the Chair of the Scientific Advisory Board of
Targeted Diagnostics & Therapeutics, Inc. (TDT; uncompensated)
• TDT provides research support to my laboratory• TDT licenses patents which are the subject of this
presentation• This technology has been sublicensed to
DiagnoCure, which does not provide support for this work
• I am entitled to a share of royalties collected by Thomas Jefferson University upon the sale of products resulting from patents on which I am an inventor
![Page 4: Clinical & Translational Science: Individualizing Cancer Immunotherapy](https://reader035.fdocuments.net/reader035/viewer/2022070422/568165d8550346895dd8e8ea/html5/thumbnails/4.jpg)
Delaware Health Sciences Alliance
![Page 5: Clinical & Translational Science: Individualizing Cancer Immunotherapy](https://reader035.fdocuments.net/reader035/viewer/2022070422/568165d8550346895dd8e8ea/html5/thumbnails/5.jpg)
Delaware Valley Institute for Clinical and Translational Science (DVICTS)
Translational Investigators
![Page 6: Clinical & Translational Science: Individualizing Cancer Immunotherapy](https://reader035.fdocuments.net/reader035/viewer/2022070422/568165d8550346895dd8e8ea/html5/thumbnails/6.jpg)
Colorectal Cancer and Women
![Page 7: Clinical & Translational Science: Individualizing Cancer Immunotherapy](https://reader035.fdocuments.net/reader035/viewer/2022070422/568165d8550346895dd8e8ea/html5/thumbnails/7.jpg)
Stage, Prognosis and Prediction
% of cases at presentation
Stage I Stage II Stage III Stage IV
% 5 yearsurvival
14
89 64 38 3
28 37 21
Stage
Recurrence (%)
20 40
Caucasian
African American
![Page 8: Clinical & Translational Science: Individualizing Cancer Immunotherapy](https://reader035.fdocuments.net/reader035/viewer/2022070422/568165d8550346895dd8e8ea/html5/thumbnails/8.jpg)
The One-Two Punch:Finding and Eradicating Occult Metastases
![Page 9: Clinical & Translational Science: Individualizing Cancer Immunotherapy](https://reader035.fdocuments.net/reader035/viewer/2022070422/568165d8550346895dd8e8ea/html5/thumbnails/9.jpg)
Guanylyl Cyclase C (GCC) as a Marker and Target in Colon Cancer
N T F Y C C E L C C N P A C A G C Y
![Page 10: Clinical & Translational Science: Individualizing Cancer Immunotherapy](https://reader035.fdocuments.net/reader035/viewer/2022070422/568165d8550346895dd8e8ea/html5/thumbnails/10.jpg)
The First Punch:Identifying Patients with Occult Metastases
![Page 11: Clinical & Translational Science: Individualizing Cancer Immunotherapy](https://reader035.fdocuments.net/reader035/viewer/2022070422/568165d8550346895dd8e8ea/html5/thumbnails/11.jpg)
Identifying Patients With Occult Metastases Using Molecular Detection
Low Risk (<5%)
High Risk (>80%)Hazard Ratio=65
![Page 12: Clinical & Translational Science: Individualizing Cancer Immunotherapy](https://reader035.fdocuments.net/reader035/viewer/2022070422/568165d8550346895dd8e8ea/html5/thumbnails/12.jpg)
The Second Punch:Eliminating Occult Metastases
![Page 13: Clinical & Translational Science: Individualizing Cancer Immunotherapy](https://reader035.fdocuments.net/reader035/viewer/2022070422/568165d8550346895dd8e8ea/html5/thumbnails/13.jpg)
Novel Vaccine Approaches to Colon Cancer: Cancer Mucosal Antigens
1
2
Tcell
APC
Cancer Mucosa Antigens
5 X
CRC Metastase
s
Effector T cells
43
![Page 14: Clinical & Translational Science: Individualizing Cancer Immunotherapy](https://reader035.fdocuments.net/reader035/viewer/2022070422/568165d8550346895dd8e8ea/html5/thumbnails/14.jpg)
20 30 400
20
40
60
80
100 ControlGCC
p<0.001
Days
Perc
ent S
urvi
val
Control GCC0
100
200
300
400
***
Immunization
Tum
or N
umbe
r
GCC Vaccine Protects Against Metastatic Colon Cancer in Mice
![Page 15: Clinical & Translational Science: Individualizing Cancer Immunotherapy](https://reader035.fdocuments.net/reader035/viewer/2022070422/568165d8550346895dd8e8ea/html5/thumbnails/15.jpg)
Individualizing Cancer Immunotherapy
20 30 400
20
40
60
80
100 ControlGCC
p<0.001
Days
Perc
ent S
urvi
val
![Page 16: Clinical & Translational Science: Individualizing Cancer Immunotherapy](https://reader035.fdocuments.net/reader035/viewer/2022070422/568165d8550346895dd8e8ea/html5/thumbnails/16.jpg)
AcknowledgementsThomas Jefferson University and Kimmel Cancer Center· Pharmacology
Stephanie Schulz Peng Li Janis Haaf Chris Bonaccorso Egeria Lin Ahmara Gibbon Michael
Valentino David Zuzga Adam Snook Alex Meija
• Medical Oncology Edith Mitchell
• Pathology Juan Palazzo
· Biostatistics Terry Hyslop
· Surgery Scott Goldstein Gerald Isenberg
Christiana Care Bruce Boman Nicholas Petrelli
Funding NIH PA
Department of Health
TDT, Inc.
![Page 17: Clinical & Translational Science: Individualizing Cancer Immunotherapy](https://reader035.fdocuments.net/reader035/viewer/2022070422/568165d8550346895dd8e8ea/html5/thumbnails/17.jpg)